You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 244 No. 8, August 22, 1980 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Clinical Experience With a Human Diploid Cell Rabies Vaccine

Larry J. Anderson, MD; William G. Winkler, DVM; Barry Hafkin, MD; Richard A. Keenlyside, MBBS; Lawrence J. D'Angelo, MD, MPH; Marc W. Deitch, MD

JAMA. 1980;244(8):781-784.


Abstract

Between January 1975 and December 1977 the Center for Disease Control treated 255 persons with the human diploid cell strain rabies vaccine who did not have development of an antibody titer to duck embryo vaccine (DEV) or who were at risk for having a serious reaction to DEV. Two hundred eighteen persons were treated postexposure, and 37 persons were treated preexposure. The antibody response to the vaccine was excellent, and the reaction rates were low. No person treated has had development of rabies. This study corroborates other studies that suggest that the human diploid cell strain rabies vaccines are safe and induce excellent antibody titers to rabies.

(JAMA 244:781-784, 1980)



Author Affiliations

From the Viral Diseases Division, Bureau of Epidemiology, Center for Disease Control, Atlanta (Drs Anderson and Winkler); Texas Department of Health, Austin (Dr Hafkin); National Institute for Occupational Safety and Health, Center for Disease Control, Cincinnati (Dr Keenlyside); Division of Internal Medicine, Department of Medicine, Georgetown University Medical Center, Washington, DC (Dr D'Angelo); and Wyeth Laboratories Division, Radnor, Pa (Dr Deitch). Drs Hafkin, Keenlyside, and D'Angelo were formerly with the Viral Diseases Division, Bureau of Epidemiology, Center for Disease Control, Atlanta.


Footnotes

Reprint requests to Viral Diseases Division, Bureau of Epidemiology, Center for Disease Control, Atlanta, GA 30333 (Dr Anderson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prophylaxis against Rabies
Rupprecht and Gibbons
NEJM 2004;351:2626-2635.
FULL TEXT  

Rhesus Diploid Rabies Vaccine (Adsorbed), A New Rabies Vaccine: II. Results of Clinical Studies Simulating Prophylactic Therapy for Rabies Exposure
Berlin et al.
JAMA 1983;249:2663-2665.
ABSTRACT  

Fatal Encephalitis Apparently due to Rabies: Occurrence After Treatment With Human Diploid Cell Vaccine But Not Rabies Immune Globulin
Devriendt et al.
JAMA 1982;248:2304-2306.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1980 American Medical Association. All Rights Reserved.